2023-08-02 17:26:02 ET
- Innoviva press release ( NASDAQ: INVA ): Q2 GAAP EPS of $0.02.
- Revenue of $80.99M (-25.2% Y/Y) beats by $13.07M .
For further details see:
Innoviva GAAP EPS of $0.02, revenue of $80.99M beats by $13.07M2023-08-02 17:26:02 ET
For further details see:
Innoviva GAAP EPS of $0.02, revenue of $80.99M beats by $13.07MMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
2024-05-12 00:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Core royalty platform on track; receiving GSK royalties of $61.9 million Achieved net product revenues of $19.1 million, representing 66% year-over-year growth driven by launch of XACDURO® and growth of key core product GIAPREZA® Strong pipeline progress: positive Phase ...
Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strate...